Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
NCT00162136
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Malignancies
Interventions
DRUG:
Ixabepilone
Sponsor
R-Pharm